不同剂量米非司酮治疗子宫肌瘤122例疗效分析

目的观察不同剂量米非司酮治疗子宫肌瘤的临床疗效和安全性。方法将122例确诊子宫肌瘤的患者分为3组，A组应用米非司酮5mg／d，B组应用米非司酮12．5mg／d，C组应用米非司酮25mg／d；月经第1天始服用，连服3个月为1疗程。用药前、用药后B超测量子宫及子宫肌瘤的三维径线；用药前和用药3个月后测定促卵泡激素（FSH）、黄体生成素（LH）、雌二醇（E2）、孕酮（P），检测血常规、肝肾功能，观察服药的不良反应。结果3组患者治疗期间均闭经，血红蛋白上升，3组子宫及肌瘤体积均明显减小，A组子宫缩小22．7％（P〈0．01），B组子宫缩小24．9％（P〈0．01），C组子宫缩小26．4％（P〈0．01），A组最大肌瘤体积比用药前缩小26．9％（P〈0．15）。B组最大肌瘤体积平均比用药前缩小28．8％（P〈0．01）。C组肌瘤体积平均缩比用药前缩小30．65％（P〈0．01）。各组治疗前后对比，差异有统计学意义（P〈0．01）；促卵泡激素（FSH）、黄体生成素（LH）、雌二醇（E2）和孕酮（P）用药前后对比，平均水平均下降，差异有统计学意义（P〈0．01）。结论小剂量米非司酮治疗子宫肌瘤疗效好，不良反应轻，为保守治疗子宫肌瘤提供了一条新的治疗途径。

Different doses of mifepristone treatment of 122 cases of uterine myoma Effect Analysis

Objective To observe the different doses of mifepristone for treatment of uterine fibroids clinical efficacy and safety. Methods 122 cases of patients with diagnosed uterine leiomyoma were divided into 3 groups, A group of application of mifepristone 5 mg / d, B group, mifepristone 12. 5 mg/ d, C group, mife- pristone 25 mg/ d; period before the 1 st day using it, even for 3 months to 1 course of treatment. Medication before the medication after the B-measurement of the uterus and uterine myoma diameter line three-dimensional; medication use before and three months after determination of follicle-stimulating hormone （FSH） , luteinizing hormone （ LH）, estradiol （ E2 ）, progesterone （ P）, detection of blood, liver and kidney function, medication side effects observed. Results 3 groups of patients with amenorrhea during treatment, hemoglobin increased 3 uterine and fibroid volume were significantly reduced, A group of the uterus to reduce 22. 7% （P 〈0. 01 ）, B group of the uterus to reduce 24.9% （ P 〈 0. 01 ）, C Group to reduce the uterus 26.4% （ P 〈 0. 01 ）, A group of the largest fibroid volume ratio before treatment to reduce 26. 9% （ P 〈 0. 15 ）. B Group the largest myoma volume before treatment to reduce the average 28. 8% （P 〈 0.01 ）. C group Fibroid volume reduction than the average pre-medication to reduce 30. 65% （P 〈 0.01 ）. Compared before and after treatment in each group, the difference was statistically significant （P 〈 0. 01 ）; follicle-stimulating hormone （FSH）, luteinizing hormone （LH）, estradiol （E2） and progesterone （P） before and after contrast administration, the average water dropped by an average, the difference was statistically significant （P 〈 0.01 ）. Conclusion Low-dose efficacy of mifepristone treatment of uterine fibroids, and adverse effects of light, for the conservative treatment of uterine fibroids provides a new way of treatment.